CTNM Company Profile and Key Details

CTNM has shown mixed momentum, gaining 29.23% over the past week and 1.28% over the past quarter, though year-to-date performance is up 3.67%. Short-term trend indicators are bearishly aligned (SMA20 4.18%, SMA50 21.25%, SMA200 66.58%). The stock’s 14-day RSI is 63.4 (firm momentum), while the ATR of 0.93 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -3.37% below its high and over 371.04% above its low. Average 10-day trading volume of 248.66 thousand shares is in line with the 3-month average of 270.44 thousand, indicating normal recent market interest.

Contineum Therapeutics, Inc. Class A Common Stock has 21.63 million shares outstanding. The public float is 14.97 million shares, elevated short interest at 3.19% of float. This equals 620.60 thousand shares. The short ratio is 2.51 days. Institutional investors hold 75.15% of the float. Insiders own 1.61%. Lorrain Daniel S. holds 143.54 thousand shares, Stengone Carmine N. has 14.95 thousand shares and Watkins Tim has 0.00 shares. Over the past six months, insider transactions show net selling. They sold 38.64 thousand shares across 16 transactions.

Wall Street analysts project EPS growth of 1.35% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $23.00 to $16.00. The high target offers 62.54% upside. The low target suggests 13.07% downside. The mean target is $20.33. This offers 43.67% upside. Contineum Therapeutics, Inc. Class A Common Stock earnings surprise history is a mixed track record. The quarter that ended March 05, 2026, missed forecasts by -2.0%. The prior quarter beat by -22.41%. Over the last six quarters, Apple has recorded several small beats. These include -2.44% in November 06, 2024.

Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ:CTNM) closed at $14.15 USD, gaining $0.95 (7.20%) from the previous close of $13.20. The stock is currently mid-range between its 52-week high and low $3.35 and $16.33. With a market capitalization of about $528.30 million, Contineum Therapeutics, Inc. Class A Common Stock is classified as a small-cap and shows market-like volatility (beta ~0.89). Key stats such as the average daily volume over the past year has been around 288.60 thousand shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, Contineum Therapeutics, Inc. Class A Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Carmine N. Stengone, the company employs approximately 41 people and listed since April 05, 2024. Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.

Contineum Therapeutics, Inc. Class A Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.43. This means the shares are trading above this model’s fair value.

Contineum Therapeutics, Inc. Class A Common Stock trades at a P/E ratio of -7.4, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.7 suggesting the stock is closer to book value. The P/FCF stands at -9.67, also below market averages.

Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ:CTNM) shares are flat 3.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Contineum Therapeutics, Inc. Class A Common Stock trading at a premium to the broader market with a P/E of -7.4. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $22.64, suggesting 60.0% upside. Our AI forecast model points to short-term weakness (-0.92% over two weeks), a medium-term rise (87.14% over three months), and a longer-term gain (238.23% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Contineum Therapeutics, Inc. Class A Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.92%, with price expected at $14.02 by May 18, 2026, within a range of $13.33 to $14.69 3-Month Outlook: Projected rise of 87.14%, reaching $26.48 by July 31, 2026, with a range of $25.96 to $27.31. 1-Year Outlook: Projected gain of 238.23%, with price at $47.86 by May 04, 2027, within a range of $48.95 to $54.45.